|
피부 편평세포암(cSCC) : 시장 인사이트, 역학, 시장 예측(-2027년)
Cutaneous Squamous cell Carcinoma (CsCC) - Market Insight, Epidemiology and Market Forecast - 2028
|
| 리서치사 |
DelveInsight Business Research LLP
|
| 발행일 |
2019년 01월 |
상품 코드 |
524523 |
| 페이지 정보 |
영문 100 Pages |
| 가격 |
|
|
피부 편평세포암(cSCC) : 시장 인사이트, 역학, 시장 예측(-2027년)
Cutaneous Squamous cell Carcinoma (CsCC) - Market Insight, Epidemiology and Market Forecast - 2028
|
| 발행일 : 2019년 01월 | 페이지 정보 : 영문 100 Pages |
|
|
주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)의 피부 편평세포암(cSCC: Cutaneous Squamous Cell Carcinoma) 시장에 대해 조사했으며, 질병 개요, 현행 치료법, 출시된 치료제 및 신약 프로파일, 주요 7개국 시장 동향, 역학적 예측, 미충족 요구, 치료제별 시장 규모 추이와 예측, 시장 성장 촉진요인 및 저해요인 등의 정보를 정리했습니다.
목차
제1장 보고서 개요
제2장 피부 편평세포암(cSCC) 시장 개요
- 주요 7개국 시장 규모(실적)
- 주요 7개국 시장 규모(예측)
제3장 질환 배경과 개요 : 피부 편평세포암(cSCC)
제4장 역학과 환자 인구
- 주요 7개국의 이환율(실적, 예측)
- 주요 7개국의 이환율 : 연령층별(실적, 예측)
- 주요 7개국의 이환율 : 성별(실적, 예측)
- 주요 7개국의 이환율 : 병기별(실적, 예측)
- 주요 7개국의 진단수, 치료 가능한 증례수(실적, 예측)
제5장 피부 편평세포암(cSCC) : 국가별 역학
- 미국
- 이환율(실적, 예측)
- 이환율 : 연령층별(실적, 예측)
- 이환율 : 성별(실적, 예측)
- 이환율 : 병기별(실적, 예측)
- 진단수, 치료 가능한 증례수(실적, 예측)
- EU 5개국
- 독일
- 이환율(실적, 예측)
- 이환율 : 연령층별(실적, 예측)
- 이환율 : 성별(실적, 예측)
- 이환율 : 병기별(실적, 예측)
- 진단수, 치료 가능한 증례수(실적, 예측)
- 프랑스
- 이환율(실적, 예측)
- 이환율 : 연령층별(실적, 예측)
- 이환율 : 성별(실적, 예측)
- 이환율 : 병기별(실적, 예측)
- 진단수, 치료 가능한 증례수(실적, 예측)
- 이탈리아
- 이환율(실적, 예측)
- 이환율 : 연령층별(실적, 예측)
- 이환율 : 성별(실적, 예측)
- 이환율 : 병기별(실적, 예측)
- 진단수, 치료 가능한 증례수(실적, 예측)
- 스페인
- 이환율(실적, 예측)
- 이환율 : 연령층별(실적, 예측)
- 이환율 : 성별(실적, 예측)
- 이환율 : 병기별(실적, 예측)
- 진단수, 치료 가능한 증례수(실적, 예측)
- 영국
- 이환율(실적, 예측)
- 이환율 : 연령층별(실적, 예측)
- 이환율 : 성별(실적, 예측)
- 이환율 : 병기별(실적, 예측)
- 진단수, 치료 가능한 증례수(실적, 예측)
- 일본
- 이환율(실적, 예측)
- 이환율 : 연령층별(실적, 예측)
- 이환율 : 성별(실적, 예측)
- 이환율 : 병기별(실적, 예측)
- 진단수, 치료 가능한 증례수(실적, 예측)
제6장 현행 치료법
제7장 출시된 치료제
- Cemiplimab : Regeneron Pharmaceuticals
- 작용기전
- 규제 마일스톤
- 장단점
- 안전성과 유효성
- 제품 개요
제8장 리포트를 참조
제9장 신약
- 주요 교차 경쟁
- Talimogene laherparepvec : Amgen
- 규제 마일스톤
- 임상 개발
- 제품 개요
- 임상 파이프라인
- Pembrolizumab : Merck Sharp＆Dohme
제10장 보고서를 참조
제11장 피부 편평세포암(cSCC) 시장 규모
제12장 주요 7개국 시장 분석 : 국가별
제13장 시장 성장 촉진요인
제14장 시장 성장 저해요인
제15장 조사 방법
제16장 DelveInsight의 서비스 내용
제17장 면책사항
제18장 DelveInsight에 대해
LSH 18.12.10※ 이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.
DelveInsight's "Cutaneous Squamous cell Carcinoma (CsCC) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Cutaneous Squamous cell Carcinoma (CsCC) epidemiology and market outlook for the 7MM.
Markets Covered
- United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2016-2028
Cutaneous Squamous cell Carcinoma (CsCC) Understanding and Treatment Algorithm
The market report provides the overview of the Cutaneous Squamous cell Carcinoma (CsCC) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.
Cutaneous Squamous cell Carcinoma (CsCC) Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Cutaneous Squamous cell Carcinoma (CsCC) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.
Cutaneous Squamous cell Carcinoma (CsCC) Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.
Cutaneous Squamous cell Carcinoma (CsCC) Market Outlook
The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Cutaneous Squamous cell Carcinoma (CsCC) market.
Cutaneous Squamous cell Carcinoma (CsCC) Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.
Cutaneous Squamous cell Carcinoma (CsCC) Report Insights
- Patient Population in Cutaneous Squamous cell Carcinoma (CsCC)
- Therapeutic Approaches in Cutaneous Squamous cell Carcinoma (CsCC)
- Cutaneous Squamous cell Carcinoma (CsCC) Pipeline Analysis
- Cutaneous Squamous cell Carcinoma (CsCC) Market Size and Trends
- Cutaneous Squamous cell Carcinoma (CsCC) Market Opportunities
- Impact of upcoming Therapies in Cutaneous Squamous cell Carcinoma (CsCC)
Cutaneous Squamous cell Carcinoma (CsCC) Report Key Strengths
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
Cutaneous Squamous cell Carcinoma (CsCC) Report Assessment
- Current Treatment Practices in Cutaneous Squamous cell Carcinoma (CsCC)
- Unmet Needs in Cutaneous Squamous cell Carcinoma (CsCC)
- Market Attractiveness
- Market Drivers and Barriers
Key Benefits
- The report will help to develop Business Strategies by understanding the trends shaping and driving the Cutaneous Squamous cell Carcinoma (CsCC) market
- Organize sales and marketing efforts by identifying the best opportunities for Cutaneous Squamous cell Carcinoma (CsCC) market
- To understand the future market competition in the Cutaneous Squamous cell Carcinoma (CsCC) market.
Table of Contents
1. Report Introduction
2. Cutaneous Squamous cell Carcinoma (CsCC) Market Overview at a Glance
- 2.1. Market Share Distribution of Cutaneous Squamous cell Carcinoma (CsCC) in 2016
- 2.2. Market Share Distribution of Cutaneous Squamous cell Carcinoma (CsCC) in 2028
3. Disease Background and Overview: Cutaneous Squamous cell Carcinoma (CsCC)
- 3.1. Introduction
- 3.2. Symptoms
- 3.3. Etiology
- 3.4. Risk Factors
- 3.5. Pathophysiology
- 3.6. Diagnosis
- 3.7. Treatment
4. Epidemiology and Patient Population
- 4.1. Key Findings
- 4.2. Total Prevalent/ Incident Patient Population of Cutaneous Squamous cell Carcinoma (CsCC) in 7MM
- 4.3. Total Prevalent Patient Population of Cutaneous Squamous cell Carcinoma (CsCC) in 7MM - By Countries
5. Epidemiology of Cutaneous Squamous cell Carcinoma (CsCC) by Countries
- 5.1. United States
- 5.1.1. Assumptions and Rationale
- 5.1.2. Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.1.3. Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
- 5.1.4. Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
- 5.1.5. Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.1.6. Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.2. EU5
- 5.3. Assumptions and Rationale
- 5.4. Germany
- 5.4.1. Assumptions and Rationale
- 5.4.2. Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.4.3. Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
- 5.4.4. Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
- 5.4.5. Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.4.6. Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.5. France
- 5.5.1. Assumptions and Rationale
- 5.5.2. Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.5.3. Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
- 5.5.4. Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
- 5.5.5. Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.5.6. Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.6. Italy
- 5.6.1. Assumptions and Rationale
- 5.6.2. Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.6.3. Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
- 5.6.4. Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
- 5.6.5. Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.6.6. Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.7. Spain
- 5.7.1. Assumptions and Rationale
- 5.7.2. Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.7.3. Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
- 5.7.4. Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
- 5.7.5. Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.7.6. Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.8. United Kingdom
- 5.8.1. Assumptions and Rationale
- 5.8.2. Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.8.3. Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
- 5.8.4. Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
- 5.8.5. Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.8.6. Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.9. Japan
- 5.9.1. Assumptions and Rationale
- 5.9.2. Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.9.3. Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
- 5.9.4. Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
- 5.9.5. Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
- 5.9.6. Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
6. Current Treatment & Medical practices
- 6.1. Treatment Algorithm
- 6.2. Treatment Guidelines
7. Unmet Needs of the Cutaneous Squamous cell Carcinoma (CsCC)
8. Marketed Therapies
- 8.1. Drug A: Company 1
- 8.1.1. Drug Description
- 8.1.2. Mechanism of Action
- 8.1.3. Regulatory Milestones
- 8.1.4. Advantages & Disadvantages
- 8.1.5. Product Profile
- 8.2. Drug B: Company 2
- 8.2.1. Drug Description
- 8.2.2. Mechanism of Action
- 8.2.3. Regulatory Milestones
- 8.2.4. Advantages & Disadvantages
- 8.2.5. Product Profile
9. Pipeline Therapies - At a glance
10. Key Cross Competition
11. Emerging Therapies for Cutaneous Squamous cell Carcinoma (CsCC)
- 11.1. Drug C: Company 3
- 11.1.1. Drug Description
- 11.1.2. Clinical Trials Details
- 11.1.3. Safety and Efficacy Profile
- 11.1.4. Advantages & Disadvantages
- 11.1.5. Pipeline Development Activities
- 11.1.6. Product Profile
- 11.2. Drug D: Company 4
- 11.2.1. Drug Description
- 11.2.2. Clinical Trials Details
- 11.2.3. Safety and Efficacy Profile
- 11.2.4. Advantages & Disadvantages
- 11.2.5. Pipeline Development Activities
- 11.2.6. Product Profile
12. Cutaneous Squamous cell Carcinoma (CsCC) : 7MM Market Analysis
- 12.1. 7MM Market Size of Cutaneous Squamous cell Carcinoma (CsCC)
- 12.2. 7MM Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC)
- 12.3. 7MM Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products
13. Cutaneous Squamous cell Carcinoma (CsCC) : Country-Wise Market Analysis
- 13.1. United States
- 13.1.1. Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in United States
- 13.1.2. Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC) in United States
- 13.1.3. Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products in United States
- 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2. EU-5
- 13.2.1. Germany
- 13.2.1.1. Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in Germany
- 13.2.1.2. Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC) in Germany
- 13.2.1.3. Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products in Germany
- 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2.2. France
- 13.2.2.1. Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in France
- 13.2.2.2. Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC) in France
- 13.2.2.3. Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products in France
- 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2.3. Italy
- 13.2.3.1. Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in Italy
- 13.2.3.2. Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC) in Italy
- 13.2.3.3. Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products in Italy
- 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2.4. Spain
- 13.2.4.1. Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in Spain
- 13.2.4.2. Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC) in Spain
- 13.2.4.3. Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products in Spain
- 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2.5. United Kingdom
- 13.2.5.1. Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in United Kingdom
- 13.2.5.2. Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC) in United Kingdom
- 13.2.5.3. Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products in United Kingdom
- 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.3. Japan
- 13.3.1. Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in Japan
- 13.3.2. Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC) in Japan
- 13.3.3. Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products in Japan
- 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
Indication Specific
|
 |
|
